Business Context and Reporting Period
This Form 8-K was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on June 2, 2009. The report discloses a material corporate event occurring on the same date.
Key Financial Metrics
The filing details a specific acquisition transaction rather than periodic financial performance metrics such as revenue, profit, or cash flow.
- Acquisition Target: Innomar Strategies Inc., a Canadian specialty pharmaceutical services company.
- Transaction Value: Approximately $15 million CAD ($13.8 million USD).
- Payment Method: Cash, subject to a working capital adjustment.
Material Changes
The primary material change is the expansion of the company's portfolio through the acquisition of Innomar Strategies Inc. No comparative financial data or changes in debt levels are provided in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the acquisition. The transaction is subject to a working capital adjustment, which represents a contingency in the final purchase price.
Investor Verification Checklist
- Verify the final purchase price after the working capital adjustment is completed.
- Confirm the integration timeline and strategic rationale for acquiring a Canadian specialty pharmaceutical services firm.
- Review subsequent filings for the impact of this acquisition on consolidated financial statements.